Streetbeat News

CRVO

CervoMed Inc.

https://www.cervomed.com

Industry

Biotechnology

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.

Open

10.99

Mkt cap

89M

Volume

67K

High

11.29

P/E Ratio

4.66

52-wk high

26.38

Low

10.46

Div yield

N/A

52-wk low

5.85

CervoMed has completed the last patient visit in its RewinD-LB Phase 2b clinical trial for neflamapimod, targeting early-stage dementia with Lewy bodies. Topline data from the trial is expected in December 2024.

Portfolio Pulse from

November 12, 2024 | 12:15 pm

CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on age-related neurologic disorders, will participate in investor conferences in November.

Portfolio Pulse from

November 07, 2024 | 1:45 pm

CervoMed Inc. has completed the last patient visit in its Phase 2b trial of neflamapimod for early-stage dementia with Lewy bodies. The company plans to report topline data in December 2024, with promising potential for cognitive and motor function improvement.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 12:18 pm

CervoMed Inc. (NASDAQ:CRVO) will present findings on neflamapimod for treating dementia with Lewy bodies at the 17th Clinical Trials on Alzheimer's Disease Conference in 2024.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 12:16 pm

Chardan Capital has initiated coverage on CervoMed (NASDAQ:CRVO) with a Buy rating and set a price target of $55.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 6:38 pm

CervoMed (NASDAQ:CRVO) reported better-than-expected Q2 2024 results with an EPS of $(0.27) beating the estimate of $(0.42) and sales of $3.29 million surpassing the $2.08 million estimate.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 12:07 pm

CervoMed Inc. (NASDAQ:CRVO) presented plasma biomarker data from its AscenD-LB Phase 2a trial at the AAIC 2024, showing that neflamapimod treatment significantly reduced plasma GFAP levels in patients with dementia with Lewy bodies (DLB), correlating with improved clinical outcomes.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 12:13 pm

Morgan Stanley has initiated coverage on CervoMed (NASDAQ:CRVO) with an Overweight rating and a price target of $35.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 10:00 am

Canaccord Genuity analyst Sumant Kulkarni maintains a Buy rating on CervoMed (NASDAQ:CRVO) with a $65 price target.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 1:09 pm

CervoMed Inc. (NASDAQ:CRVO) will be added to the Russell 2000 and Russell 3000 Indexes effective July 1, 2024, as part of the annual reconstitution of the Russell U.S. Indexes.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 12:03 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.